BlackRock Advisors’s AIM ImmunoTech AIM Stock Holding History

BlackRock Advisors’s Portfolio AIM Stock Details AIM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$4K	Hold	1	–	–	﹤0.01%	3656
2016 Q3	$7K	Hold	1	–	–	﹤0.01%	3624
2016 Q2	$8K	Hold	1	–	–	﹤0.01%	3629
2016 Q1	$9K	Hold	1	–	–	﹤0.01%	3599
2015 Q4	$6K	Hold	1	–	–	﹤0.01%	3714
2015 Q3	$12K	Hold	1	–	–	﹤0.01%	3637
2015 Q2	$14K	Buy	+1	New	+$12.4K	﹤0.01%	3579
2015 Q1	–	Hold	0	–	–	–	3598
2014 Q4	–	Hold	0	–	–	–	3673
2014 Q3	–	Hold	0	–	–	–	3647
2014 Q2	–	Hold	0	–	–	–	3653
2014 Q1	–	Hold	0	–	–	–	3614
2013 Q4	–	Hold	0	–	–	–	3618
2013 Q3	–	Hold	0	–	–	–	3607
2013 Q2	–	Hold	0	–	–	–	3586

Other funds holding AIM

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

OAM

Occidental Asset Management Burlingame, California $1.01B AUM 29.59% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

BlackRock Advisors's AIM Position: Q4 2016 in Review

BlackRock Advisors held its AIM ImmunoTech (AIM) position steady in Q4 2016 at 1 share worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #3656.

BlackRock Advisors first reported a position in AIM in Q2 2015 and has held it in 7 quarters since. The position peaked at $14K in Q2 2015. 14 funds tracked by Wall St. Rank hold AIM as of Q4 2016.

BlackRock Advisors held 1 share of AIM ImmunoTech worth $4K as of Q4 2016.
BlackRock Advisors left its AIM ImmunoTech share count unchanged in Q4 2016.
AIM ImmunoTech made up ﹤0.01% of BlackRock Advisors's portfolio in Q4 2016, its #3656 holding.
BlackRock Advisors first reported a position in AIM ImmunoTech in Q2 2015 and has held it in 7 quarters since.
BlackRock Advisors's AIM ImmunoTech position peaked at $14K in Q2 2015.
14 funds tracked by Wall St. Rank held AIM ImmunoTech as of Q4 2016.

Based on BlackRock Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.